Kantonsspital Baden
Baden, Switzerland
20 recruiting
Showing 1–20 of 35 trials
Recruiting
Phase 3
Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention
Dietary ExposureNephrolithiasisKidney Stone
Insel Gruppe AG, University Hospital Bern400 enrolled21 locationsNCT06653738
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-small Cell Lung Cancer (NSCLC)
Amgen750 enrolled404 locationsNCT05920356
Recruiting
Phase 2Phase 3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Non-small Cell Lung Cancer
Bristol-Myers Squibb500 enrolled186 locationsNCT07100080
Recruiting
Phase 3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,630 enrolled266 locationsNCT07213804
Recruiting
Phase 3
Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis
Venous Thromboembolism (VTE)Postpartum
Marc Blondon9,200 enrolled8 locationsNCT07140211
Recruiting
Not Applicable
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
Deep Venous ThrombosisVenous ThromboembolismPost Thrombotic Syndrome
Inari Medical300 enrolled64 locationsNCT05701917
Recruiting
Phase 2
Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)
Recurrent Prostate Cancer
Swiss Cancer Institute42 enrolled11 locationsNCT07365423
Recruiting
Phase 3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Eli Lilly and Company700 enrolled366 locationsNCT06890598
Recruiting
Phase 2Phase 3
Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
Metastatic NSCLC - Non-Small Cell Lung Cancer
Swiss Cancer Institute230 enrolled11 locationsNCT07149649
Recruiting
Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer
Metastatic Colorectal CancerBRAF V600E Mutation
Swiss Cancer Institute30 enrolled13 locationsNCT07617610
Recruiting
Phase 2
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
Extensive Stage Lung Small Cell Cancer
ETOP IBCSG Partners Foundation48 enrolled19 locationsNCT07203053
Recruiting
LUCINAE Registry: Thoracic Cancers During Pregnancy
Lung CancerThoracic CancerCancer During Pregnancy
Oncology Institute of Southern Switzerland100 enrolled4 locationsNCT07699861
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Non-small Cell Lung CancerKRAS G12C Lung Cancer
Hoffmann-La Roche600 enrolled260 locationsNCT06793215
Recruiting
Phase 1
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Advanced Metastatic Castration-resistant Prostate CancerProstate Specific Membrane Antigen (PSMA) Expression
Bayer198 enrolled35 locationsNCT06217822
Recruiting
Phase 3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Non-small Cell Lung Cancer, HER2 Mutation
Bayer444 enrolled285 locationsNCT06452277
Recruiting
Phase 2
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate Cancer
Swiss Cancer Institute162 enrolled13 locationsNCT06401980
Recruiting
DESTINY Breast Respond HER2-(Ultra)Low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer+1 more
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company2,295 enrolled211 locationsNCT05945732
Recruiting
Phase 3
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Follicular Lymphoma ( FL)
Regeneron Pharmaceuticals822 enrolled190 locationsNCT06091254
Recruiting
Modeling and Workflow Recognition for the Anterior Approach in Total Hip Arthroplasty
Hip Prosthesis
Philipp Fürnstahl60 enrolled3 locationsNCT05993845
Recruiting
Phase 2
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
SCLC,Extensive StageSLFN11-positive
ETOP IBCSG Partners Foundation44 enrolled18 locationsNCT05718323